DarioHealth Corp. (NASDAQ:DRIO) filed its third-quarter 2026 financial results on November 12, 2026, reporting revenue of $5.3 million for the quarter ended September 30, 2026, alongside updates on commercial partnerships and platform expansion.

Key Highlights

  • Revenue of $5.3 million: Up 6% year-over-year and 3% sequentially from $5.0 million and $5.2 million in Q3 2025 and Q2 2026, respectively, according to the filing.
  • GAAP gross margin of 59%: Compared with 60% in Q3 2025 and 62% in Q2 2026; non-GAAP B2B2C gross margin remained at approximately 80% for the 11th consecutive quarter.
  • Operating expenses declined 10% year-over-year to $11.2 million, while operating loss improved 15% year-over-year, the company disclosed.
  • Cash position of $31.2 million: Cash, cash equivalents, and short-term deposits totaled $31.2 million as of September 30, 2026.
  • New health plan signed: One of New Jersey's largest health plans, representing approximately 1.5 million covered lives, was signed through the Amwell channel partnership, with revenue contribution expected to begin in 2027.
  • Contracted and late-stage ARR of $13.1 million: Across more than 180 signed accounts, with more than 80% relating to multi-condition opportunities, according to the filing.
  • DarioIQ engagement impact: The filing stated that DarioIQ could contribute to an increase of up to approximately 14% in engagement-based B2B2C ARR from existing customers.

DarioHealth Reports Q3 2026 Results: Revenue Growth, Cost Reduction, and Platform Expansion

According to the filing, DarioHealth's third-quarter 2026 revenue of $5.3 million was driven primarily by growth in direct-to-consumer sales, which increased approximately 48% year-over-year. The company disclosed that business-to-business (B2B) and B2B2C revenue decreased compared to 2025, "reflecting the non-renewal of several of Twill's legacy contracts, partially offset by growth from channel partners." Gross profit increased to $3.1 million, up approximately 4% year-over-year, with the GAAP gross margin declining modestly due to a higher direct-to-consumer revenue mix and a lower IEEPA tariff refund benefit compared to Q2 2026.

On the operating side, the company reported that operating expenses of $11.2 million rose 16% quarter-over-quarter, a sequential increase the filing attributed primarily to higher stock-based compensation, which was $2.2 million in Q3 compared with $0.6 million in Q2 2026. The 10% year-over-year reduction in operating expenses was described in the filing as having multiple contributors, including DarioIQ, the company's generative AI layer. The filing noted that channel-sourced business grew more than 2x year-over-year across multiple contracting paths.

The filing also described two new product launches: Dario Women and Dario Sleep, extending the platform into menopause, perimenopause, and obstructive sleep apnea. The company disclosed that nearly 45% of its current book of business consists of women over age 40. Additionally, the filing referenced a third-party analysis of 17 studies supporting an estimated 2.5% to 7.2% annual reduction in total healthcare costs, representing approximately $3.8 million to $10.8 million in annual savings for a representative population of 20,000 covered lives, and findings of $5,077 in annual healthcare savings per user with type 2 diabetes.

What Was Disclosed

DarioHealth disclosed Q3 2026 financial results including $5.3 million in revenue, a 59% GAAP gross margin, $11.2 million in operating expenses, and $31.2 million in cash. The filing also covered new health plan signings, platform launches, and ARR metrics.